Immunovant

IMVT

Market cap $3.05B

Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?

Immunovant stock jumps 11% after new batoclimab study results showed durable thyroid hormone control in Graves' disease patients.

Wednesday might have been a Hump Day of a slog to some investors, but not for those holding shares of Immunovant (IMVT 10.82%). On some rather encouraging news from the laboratory, the clinical-stage biotech's shares gained almost 11% in value, easily topping the 0.5% rise of the benchmark S&P 500 (^GSPC 0.51%).

NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today shared an abstract with six-month off-treatment data in uncontrolled Graves' disease (GD) patients treated with batoclimab for 24 weeks, to be presented at the 2025 Annual Meeting of the American Thyroid Association (ATA) on September 11, 2025.

LOS ANGELES--(BUSINESS WIRE)---- $IMVT--IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm.

IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for the quarter ended June 30, 2025.

Immunovant (IMVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The mean of analysts' price targets for Immunovant (IMVT) points to a 137.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.